This is a StreetInsider.com Premium Only Page

HighPoint Resources (HPR) – StreetInsider.com Reports

Oct 2, 2023 08:02 AM Horizon Therapeutics (HZNP) Announces New UPLIZNA (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023

Sep 29, 2023 10:00 AM Horizon Therapeutics (HZNP) Reports New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA

Jun 30, 2023 12:31 PM Horizon Therapeutics (HZNP) Says New Analysis of MRI Findings Shows UPLIZNA Reduced Formation of Subclinical Spinal Cord Lesions in People With NMOSD

Jun 26, 2023 11:00 AM Horizon Therapeutics (HZNP) Announces TEPEZZA Approved in Brazil for the Treatment of Active Thyroid Eye Disease

Jun 22, 2023 08:02 AM Horizon Therapeutics (HZNP) Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA for Treatment of Active Thyroid Eye Disease

Jun 12, 2023 08:05 AM Horizon Therapeutics (HZNP) Reports Publication of UPLIZNA Data

Apr 14, 2023 08:16 AM Horizon Therapeutics (HZNP) Announces FDA Approval of Update to Indication Language for TEPEZZA to Specify its Use in TED Patients Regardless of Disease Activity or Duration

Mar 14, 2023 11:16 AM Horizon Therapeutics (HZNP) Announces New Analysis of MRI Findings Show UPLIZNA Reduced Formation of Asymptomatic Optic Nerve Lesions in People With NMOSD

Jan 18, 2023 08:03 AM Horizon Therapeutics (HZNP) Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population

Jan 4, 2023 08:01 AM Horizon Therapeutics (HZNP) enrolls first patient in Phase 2 of daxdilimab to treat DLE

Dec 8, 2022 08:04 AM Arrowhead Pharmaceuticals (ARWR), Horizon Therapeutics (HZNP) enrolls first patient in HZN-457 phase 1 trial for gout

Nov 16, 2022 08:11 AM Horizon Therapeutics (HZNP) Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation

Nov 8, 2022 10:01 AM Horizon Therapeutics (HZNP) Announces Sustained Patient Response to KRYSTEXXA Injection with Methotrexate Compared to KRYSTEXXA Alone

Sep 9, 2022 08:00 AM Horizon Therapeutics (HZNP) Announces $500 Million Share Repurchase Program

Aug 15, 2022 08:14 AM Q32 Bio and Horizon Therapeutics (HZNP) Announce Collaboration in Autoimmune Diseases

Jun 24, 2022 12:34 PM Horizon Therapeutics (HZNP) Announces New Analysis Finds UPLIZNA Effective Among European Populations with NMOSD

Jun 15, 2022 08:33 AM Horizon Therapeutics (HZNP) Submits Regulatory Filing for UPLIZNA in Brazil

May 3, 2022 09:15 AM Horizon Therapeutics (HZNP) Announces Phase 2 Study of Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis

May 2, 2022 06:27 AM Horizon Therapeutics (HZNP) Receives European Commission Approval of UPLIZNA for Treatment of Adults With Neuromyelitis Optica Spectrum Disorder

Feb 15, 2022 11:02 AM Horizon Therapeutics (HZNP) Announces New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA Comparable with Clinical Trial Observations

Jan 10, 2022 07:31 AM Horizon Therapeutics (HZNP) Submits sNLA for Concomitant Use of KRYSTEXXA Plus Methotrexate for People Living with Uncontrolled Gout

Dec 16, 2021 08:02 AM Alpine Immune Sciences (ALPN) and Horizon Therapeutics (HZNP) Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases

Nov 12, 2021 07:30 AM Horizon Therapeutics (HZNP) Receives CHMP Positive Opinion for UPLIZNA as Monotherapy for Treatment of Adult Patients with Neuromyelitis Optica Spectrum Disorder

Oct 25, 2021 08:04 AM Horizon Therapeutics (HZNP) Announces MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA with Methotrexate

Oct 21, 2021 12:02 PM Horizon Therapeutics (HZNP) Announces Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease

Oct 4, 2021 08:34 AM Horizon Therapeutics (HZNP) Announces New Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA for Treatment of NMOSD

Oct 4, 2021 08:08 AM Horizon Therapeutics (HZNP) Announces New UPLIZNA Data in Neuromyelitis Optica Spectrum Disorder (NMOSD)

Sep 23, 2021 08:30 AM Horizon Therapeutics (HZNP) New Data Shows UPLIZNA Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder

Sep 21, 2021 07:31 AM Horizon Therapeutics (HZNP) Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline

Sep 7, 2021 08:32 AM Horizon Therapeutics (HZNP) Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease

Jun 29, 2021 08:02 AM Horizon Therapeutics (HZNP) Enrolls First Patient in Phase 2 Trial of HZN-7734 for the Treatment of Systemic Lupus Erythematosus

Jun 21, 2021 07:32 AM Arrowhead Pharmaceuticals (ARWR), Horizon Therapeutics (HZNP) Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout

Jun 18, 2021 12:32 PM Horizon Therapeutics (HZNP) Announces Multiple Presentations on NMOSD at EAN

Jun 17, 2021 07:06 AM Horizon Therapeutics (HZNP) Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics

May 6, 2021 08:34 AM Horizon Therapeutics (HZNP) Announces New Analysis of UPLIZNA for Neuromyelitis Optica Spectrum Disorder Published in Neurology Neuroimmunology & Neuroinflammation

Apr 16, 2021 08:03 AM Horizon Therapeutics (HZNP) Announces New Integrated Data and Follow-up Outcomes From Two TEPEZZA Pivotal Trials Published in The Lancet Diabetes & Endocrinology

Apr 7, 2021 08:03 AM Horizon Therapeutics (HZNP) RECIPE Randomized Controlled Trial Data Published in Arthritis & Rheumatology Show Higher Response Rates Using KRYSTEXXA with Immunomodulator Mycophenolate Mofetil

Apr 5, 2021 08:36 AM Horizon Therapeutics (HZNP) Announces New UPLIZNA Data in People With Neuromyelitis Optica Spectrum Disorder to be Presented at AAN's 73rd Annual Meeting

Mar 30, 2021 07:34 AM Horizon Therapeutics (HZNP) to Resupply Market With TEPEZZA for the Treatment of Thyroid Eye Disease Beginning in April

Mar 25, 2021 08:51 AM HighPoint Resources (HPR) is not aware of any material, undisclosed corporate developments (earlier)

Mar 24, 2021 02:43 PM HighPoint Resources (HPR) Halted News Pending

Mar 24, 2021 08:16 AM Horizon Therapeutics (HZNP) Announces UPLIZNA Approved by Japanese Ministry of Health, Labour and Welfare for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder

Jan 11, 2021 07:04 AM Horizon Therapeutics (HZNP) Provides Preliminary 2020 Financial Results

Nov 23, 2020 08:05 AM Horizon Therapeutics (HZNP) and Halozyme Therapeutics (HALO) Enter Global Collaboration and License Agreement for ENHANZE® Technology

Nov 13, 2020 08:34 AM Horizon Therapeutics (HZNP) Reports New TEPEZZA (teprotumumab-trbw) Data Presented at AAO 2020 Virtual

Nov 10, 2020 05:03 PM HighPoint Resources (HPR) Receives Continued Listing Standard Notice from NYSE

Nov 9, 2020 06:50 AM Bonanza Creek Energy (BCEI) to Acquire Restructured HighPoint Resources (HPR)

Nov 2, 2020 02:00 PM Horizon Therapeutics (HZNP) Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA Concomitantly Used with the Immunomodulator Mycophenolate Mofetil

Oct 20, 2020 08:18 AM HighPoint Resources (HPR) Announces 1-for-50 Reverse Stock Split

Oct 14, 2020 08:03 AM Horizon Therapeutics (HZNP) Reports TEPEZZA (teprotumumab-trbw) Data from Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease